Last reviewed · How we verify
Fixed low dose tinzaparin
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboprophylaxis in medical patients, Thromboprophylaxis in surgical patients.
At a glance
| Generic name | Fixed low dose tinzaparin |
|---|---|
| Also known as | tinzaparin, Innohep |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect target); Coagulation factors Xa and IIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Thromboembolism |
| Phase | FDA-approved |
Mechanism of action
Tinzaparin is derived from unfractionated heparin through chemical depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 5,000 and 10,000 Da. It potentiates antithrombin III-mediated inhibition of coagulation factors, particularly factor Xa (anti-Xa activity) with some anti-IIa activity. The fixed low-dose formulation is used for thromboprophylaxis in specific clinical settings.
Approved indications
- Thromboprophylaxis in medical patients
- Thromboprophylaxis in surgical patients
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Heparin-induced thrombocytopenia (HIT)
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PHASE3)
- Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis (PHASE2, PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 (PHASE4)
- Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism (NA)
- Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome. (PHASE2, PHASE3)
- Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: